Clear Impact logo

Department of Vermont Health Access - Medicaid Global Commitment (STD) and 1 more... less...

Vermont Medicaid (GC-17)

CHL: Chlamydia Screening in Women (GC-17)

Current Value

50.8%

2017

Definition

Line Bar

Notes on Methodology

  • The annual reported rate captures activity during the previous calendar year.  For example, the 2017 rate captures services provided during calendar year 2016.
  • This is a Healthcare Effectiveness & Data Information Set (HEDIS) administrative measure.
  • Based on the advice of their External Quality Review Organization (EQRO), DVHA’s rates only include only Medicaid Primary beneficiaries in HEDIS administrative measures as of 2014.
  • The target trend line is the 50th percentile national benchmark for Medicaid programs.

Story Behind the Curve

This measure assesses the percentage of sexually active women 16-24 years of age who were screened for chlamydia during the measurement year. Screening is essential because the majority of women who have the condition do not experience symptoms. The main objective of chlamydia screening is to prevent pelvic inflammatory disease (PID), infertility and ectopic pregnancy, all of which have very high rates of occurrence among women with untreated chlamydia infection.

Chlamydia trachomatis is the most common sexually transmitted disease (STD) in the U.S. Risk factors associated with becoming infected with chlamydia are the same risks for contracting other STD’s (e.g., multiple sex partners). Chlamydia is more prevalent among adolescent and young adult women.


Last updated:  August 2017

Author:  DVHA Quality Unit

Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.

Scorecard Container Measure Action Actual Value Target Value Tag S A m/d/yy m/d/yyyy